KR20180015461A - The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia - Google Patents

The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia Download PDF

Info

Publication number
KR20180015461A
KR20180015461A KR1020160099002A KR20160099002A KR20180015461A KR 20180015461 A KR20180015461 A KR 20180015461A KR 1020160099002 A KR1020160099002 A KR 1020160099002A KR 20160099002 A KR20160099002 A KR 20160099002A KR 20180015461 A KR20180015461 A KR 20180015461A
Authority
KR
South Korea
Prior art keywords
gastritis
pancreatin
irritable bowel
component
bowel syndrome
Prior art date
Application number
KR1020160099002A
Other languages
Korean (ko)
Inventor
나도현
Original Assignee
나도현
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나도현 filed Critical 나도현
Priority to KR1020160099002A priority Critical patent/KR20180015461A/en
Publication of KR20180015461A publication Critical patent/KR20180015461A/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a triple layered tablet medicine for treating gastritis with irritable bowel syndrome and functional dyspepsia, which comprises: a wood pulp paper substrate having a thickness of 0.3 to 0.4 mm; and a layer of a material to be imprinted having a thickness of 0.5 and 0.7 mm, and having an outer surface. According to the present invention, stability and strength of a structural tree panel are improved.

Description

과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염을 치료하는 삼중정 치료제{The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia}[0002] The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia has been used for treating gastritis with irritable bowel syndrome and functional dyspepsia.

본 발명은 과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염을 치료하는 삼중정 치료제 에 관한 것으로서,The present invention relates to a triple therapy for treating gastrointestinal irritation accompanied by irritable bowel syndrome and functional dyspepsia,

더욱 상세하게는 위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제에 있어서,More particularly, the present invention relates to a therapeutic agent for gastritis, irritable bowel syndrome, and functional dyspepsia,

1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 라니티딘염산염은 위염을 치료하기 위해 트리메부틴말레산염 및 판크레아틴으로 구성된 원형의 이중정을 라니티딘염산염 성분으로 코팅하여 삼중정으로 성형한 라니티딘염산염 성분으로 코팅된 삼중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 판크레아틴은 기능성 소화 불량을 치료하기 위해 판크레아틴 성분을 포함하는 이중정으로 성형한 판크레아틴 성분을 포함하는 이중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 트리메부틴말레산염은 과민성 대장 증후군을 치료하기 위해 트리메부틴말레산염 성분을 포함하는 이중정으로 성형한 트리메부틴말레산염 성분을 포함하는 이중정으로 구성 하여서,Of the three components that constitute a triple tablet as a single therapeutic agent, lanitidine hydrochloride is a compound that is prepared by coating a circular dice consisting of trimesbutin maleate and pancreatin with a component of lanitidine hydrochloride to treat gastritis, Among the three components that constitute the triple tablet as a triple-coated tablet and one therapeutic agent, pancreatin is a double-edged tablet containing a pancreatin component formed of a pancreatin-containing pancreatin component to treat functional dyspepsia, Among the three components constituting the triple tablet as one therapeutic agent, trimesbutyne maleate includes a trimethylbutynin maleate component molded into a dimept containing a trimesbutin maleate component to treat irritable bowel syndrome A double crystal,

과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염을 3종의 성분으로 구성된 1개의 삼중정으로 치료함으로써 복용의 편의성과 경제적 효율성이 상승하도록 함을 목적으로 한 것이다.The purpose of this study was to improve the convenience of use and economic efficiency by treating the irritable bowel syndrome and gastritis with functional dyspepsia with one triple tablet consisting of three components.

일반적으로 위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제는 위염, 과민성 대장 증후군, 기능성 소화 불량을 각 단일 성분의 치료제가 치료하는 것이다.In general, gastritis, irritable bowel syndrome, and functional dyspepsia are treatments for gastritis, irritable bowel syndrome, and functional dyspepsia.

상기한 바와 같이 위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제는 라니티딘염산염 단일 성분의 치료제, 트리메부틴말레산염 단일 성분의 치료제, 판크레아틴 단일 성분의 치료제로 구성된 것이다.As described above, the gastritis therapeutic agent, the irritable bowel syndrome therapeutic agent, and the functional dyspepsia treatment agent are composed of a single component of ranitidine hydrochloride, a single component of trimesbutin maleate, and a single component of pancreatin.

이상과 같은 위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제는 위염을 치료하기 위해 라니티딘염산염 단일 성분의 치료제를 복용하고, 과민성 대장 증후군을 치료하기 위해 트리메부틴말레산염 단일 성분의 치료제를 따로 복용하며, 기능성 소화 불량을 치료하기 위해 판크레아틴 단일 성분의 치료제를 따로 복용하는 것이다.In order to treat gastritis, irritable bowel syndrome, and functional dyspepsia, a treatment with single component of ranitidine hydrochloride is used to treat gastritis, and a single component of trimesbutin maleate is taken separately to treat irritable bowel syndrome. And to take a single-agent treatment with pancreatin to treat functional dyspepsia.

그러나 상기한 바와 같은 종래의 위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제는 과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염 환자의 경우 3개의 치료제를 개별적으로 복용해야 하는 번거로움 및 약가 상승에 따른 경제적 비용 부담 발생의 문제점이 있었다.However, in the case of gastritis patients suffering from irritable bowel syndrome and functional dyspepsia, the conventional treatments for gastritis, irritable bowel syndrome, and functional dyspepsia as mentioned above are troublesome to take separately the three treatments, There was a problem of incurring an economic cost burden.

대한민국 특허(실용신안) 공개 제1020030043153호Korean Patent (utility model) Publication No. 1020030043153

이에 본 발명은 종래의 위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제가 과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염 환자의 경우 3개의 치료제를 개별적으로 복용해야 하는 번거로움 및 약가 상승에 따른 경제적 비용 부담 발생의 문제점을 해결하기 위한 것이다.Accordingly, the present invention relates to a pharmaceutical composition for treating gastritis, irritable bowel syndrome, and functional dyspepsia, which is a conventional gastritis treating agent, a functional dyspepsia treating agent, an irritable bowel syndrome and a gastritis with functional dyspepsia, Thereby solving the problem of the occurrence of a cost burden.

즉, 본 발명은 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 라니티딘염산염은 위염을 치료하기 위해 트리메부틴말레산염 및 판크레아틴으로 구성된 원형의 이중정을 라니티딘염산염 성분으로 코팅하여 삼중정으로 성형한 라니티딘염산염 성분으로 코팅된 삼중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 판크레아틴은 기능성 소화 불량을 치료하기 위해 판크레아틴 성분을 포함하는 이중정으로 성형한 판크레아틴 성분을 포함하는 이중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 트리메부틴말레산염은 과민성 대장 증후군을 치료하기 위해 트리메부틴말레산염 성분을 포함하는 이중정으로 성형한 트리메부틴말레산염 성분을 포함하는 이중정으로 구성한 것이다.That is, in the present invention, among the three components constituting the triple tablet as one therapeutic agent, the lanitidine hydrochloride is prepared by coating a circular double crystal composed of trimesbutin maleate and pancreatin with a ranitidine hydrochloride component to treat gastritis, Among the three components that constitute the triple tablet as a triple tablet coated with the ranitidine hydrochloride ingredient molded into the form of a pancreatin, the pancreatin has a pancreatin-containing pancreatin-containing pancreatin component Among the three components constituting the triple tablet as a single treatment agent, trimesbutin maleate is used as a therapeutic agent for the treatment of irritable bowel syndrome, in which the trimébutynin maleate And a double crystal containing an acid salt component.

따라서 본 발명은 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 라니티딘염산염은 위염을 치료하기 위해 트리메부틴말레산염 및 판크레아틴으로 구성된 원형의 이중정을 라니티딘염산염 성분으로 코팅하여 삼중정으로 성형한 라니티딘염산염 성분으로 코팅된 삼중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 판크레아틴은 기능성 소화 불량을 치료하기 위해 판크레아틴 성분을 포함하는 이중정으로 성형한 판크레아틴 성분을 포함하는 이중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 트리메부틴말레산염은 과민성 대장 증후군을 치료하기 위해 트리메부틴말레산염 성분을 포함하는 이중정으로 성형한 트리메부틴말레산염 성분을 포함하는 이중정으로 구성 함으로써, 과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염을 3종의 성분으로 구성된 1개의 삼중정으로 치료함으로써 복용의 편의성과 경제적 효율성이 상승하도록 한 효과를 갖는 것이다.Therefore, in the present invention, among the three components constituting the triple tablet as one therapeutic agent, the lanitidine hydrochloride is prepared by coating a circular dice consisting of trimesbutin maleate and pancreatin with the component of lanitidine hydrochloride to treat gastritis, Among the three components constituting the triple tablet with the formulated lanitidine hydrochloride ingredient, one of the three components constituting the triple tablet, the pancreatin is composed of a pancreatin-containing pancreatin-containing pancreatin component to treat the functional dyspepsia Among the three components that make up the triplet as a single agent, trimébutine maleate, trimébutine maleate, which has been formulated with a double-cleaved trimébutine maleate component to treat irritable bowel syndrome Component, the irritable bowel syndrome and functional < RTI ID = 0.0 > Gastritis accompanied by indigestion is treated with one triple tablet consisting of three kinds of ingredients, so that the convenience of taking and the economic efficiency are improved.

도 1: 본 발명의 상세도Figure 1: Detail view of the present invention

즉 본 발명은 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 라니티딘염산염은 위염을 치료하기 위해 트리메부틴말레산염 및 판크레아틴으로 구성된 원형의 이중정을 라니티딘염산염 성분으로 코팅하여 삼중정으로 성형한 라니티딘염산염 성분으로 코팅된 삼중정(100), 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 판크레아틴은 기능성 소화 불량을 치료하기 위해 판크레아틴 성분을 포함하는 이중정으로 성형한 판크레아틴 성분을 포함하는 이중정(200), 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 트리메부틴말레산염은 과민성 대장 증후군을 치료하기 위해 트리메부틴말레산염 성분을 포함하는 이중정으로 성형한 트리메부틴말레산염 성분을 포함하는 이중정(300)으로 구성 된 것이다.That is, among the three components constituting the triple tablet as a single therapeutic agent, lanitidine hydrochloride is prepared by coating a circular double-layer composed of trimesbutin maleate and pancreatin with a component of lanitidine hydrochloride to treat gastritis, Among the three components that constitute the triple tablet as a triple tablet (100) coated with the molded lanitidine hydrochloride component, pancreatin is a tablet that is molded with a pancreatin containing a pancreatin component to treat functional dyspepsia Trimebutin maleate, among the three components constituting the triplet as a single therapeutic agent, is formulated as a double tablet containing trimesbutin maleate component to treat irritable bowel syndrome (300) comprising a trimesubutin maleate component.

이하, 본 발명의 사용과정에 대하여 설명하면 다음과 같다.Hereinafter, the use process of the present invention will be described.

상기한 바와 같이 본 발명은 위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제에 있어서 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 라니티딘염산염은 위염을 치료하기 위해 트리메부틴말레산염 및 판크레아틴으로 구성된 원형의 이중정을 라니티딘염산염 성분으로 코팅하여 삼중정으로 성형한 라니티딘염산염 성분으로 코팅된 삼중정(100), 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 판크레아틴은 기능성 소화 불량을 치료하기 위해 판크레아틴 성분을 포함하는 이중정으로 성형한 판크레아틴 성분을 포함하는 이중정(200), 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 트리메부틴말레산염은 과민성 대장 증후군을 치료하기 위해 트리메부틴말레산염 성분을 포함하는 이중정으로 성형한 트리메부틴말레산염 성분을 포함하는 이중정(300)으로 구성된 본 발명을 적용하여 실시하게 되면, 과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염 환자의 경우 3개의 치료제를 개별적으로 복용해야 하는 번거로움 및 약가 상승에 따른 경제적 비용 부담 발생의 문제점을 해소하도록 한 것이다.As described above, among the three components constituting the triple tablet as one therapeutic agent in the treatment of gastritis, irritable bowel syndrome, and functional dyspepsia, lanitidine hydrochloride is used to treat gastritis, Among the three components of the triplet (100) coated with the lanitidine hydrochloride component coated with the lanthidine hydrochloride component coated with the lanitidine hydrochloride component, the pancreatin composed of pancreatin, Among the three components constituting the triplet as one treatment agent, trismebutine maleate is an irritable bowel (200), which contains pancreatin component, Syndrome with a trimesubutin maleate component (300), which contains the rimetinic maleate component, when applied to the gastrointestinal disorder patients with irritable bowel syndrome and functional dyspepsia, it is necessary to take the three therapeutic agents individually, Thereby solving the problem of the economic cost burden due to the rise.

100. 라니티딘염산염 성분으로 코팅된 삼중정, 200. 판크레아틴 성분을 포함하는 이중정, 300. 트리메부틴말레산염 성분을 포함하는 이중정100. A ternary tablet coated with a component of ranitidine hydrochloride, 200. A dendrimer comprising a pancreatin component, 300. A dendrimer comprising a trimesbutin maleate component

Claims (1)

위염 치료제, 과민성 대장 증후군 치료제, 기능성 소화 불량 치료제에 있어서,
1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 라니티딘염산염은 위염을 치료하기 위해 트리메부틴말레산염 및 판크레아틴으로 구성된 원형의 이중정을 라니티딘염산염 성분으로 코팅하여 삼중정으로 성형한 라니티딘염산염 성분으로 코팅된 삼중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 판크레아틴은 기능성 소화 불량을 치료하기 위해 판크레아틴 성분을 포함하는 이중정으로 성형한 판크레아틴 성분을 포함하는 이중정, 1개의 치료제로 삼중정을 구성하고 있는 3종의 성분 중에서 트리메부틴말레산염은 과민성 대장 증후군을 치료하기 위해 트리메부틴말레산염 성분을 포함하는 이중정으로 성형한 트리메부틴말레산염 성분을 포함하는 이중정으로 구성 된 것을 특징으로 하는 과민성 대장 증후군 및 기능성 소화 불량을 동반한 위염을 치료하는 삼중정 치료제.In the treatment of gastritis, irritable bowel syndrome, and functional dyspepsia,
Of the three components that constitute a triple tablet as a single therapeutic agent, lanitidine hydrochloride is a compound that is prepared by coating a circular dice consisting of trimesbutin maleate and pancreatin with a component of lanitidine hydrochloride to treat gastritis, Among the three components that constitute the triple tablet as a triple-coated tablet and one therapeutic agent, pancreatin is a double-edged tablet containing a pancreatin component formed of a pancreatin-containing pancreatin component to treat functional dyspepsia, Among the three components constituting the triple tablet as one therapeutic agent, trimesbutin maleate includes a trimethylbutynin maleate component molded into a double-sided form containing a trimesbutin maleate component to treat irritable bowel syndrome Irritable bowel syndrome and functional digestion Triple therapy that treats gastritis with bad.
KR1020160099002A 2016-08-03 2016-08-03 The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia KR20180015461A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020160099002A KR20180015461A (en) 2016-08-03 2016-08-03 The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160099002A KR20180015461A (en) 2016-08-03 2016-08-03 The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia

Publications (1)

Publication Number Publication Date
KR20180015461A true KR20180015461A (en) 2018-02-13

Family

ID=61231804

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160099002A KR20180015461A (en) 2016-08-03 2016-08-03 The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia

Country Status (1)

Country Link
KR (1) KR20180015461A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763880A (en) * 2023-07-31 2023-09-19 浙江省立同德医院(浙江省精神卫生研究院) Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763880A (en) * 2023-07-31 2023-09-19 浙江省立同德医院(浙江省精神卫生研究院) Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation
CN116763880B (en) * 2023-07-31 2024-01-30 浙江省立同德医院(浙江省精神卫生研究院) Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation

Similar Documents

Publication Publication Date Title
BRPI0508769A (en) tamper-resistant dosage form comprising an adsorbent and an adverse agent
Iorizzo et al. Today's treatments options for onychomycosis
MX2009009623A (en) Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors.
UA90521C2 (en) Pharmaceutical composition comprising simvastatin and ezetimibe
EA201390409A1 (en) COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL-SOLUBLE COATING
WO2009139576A3 (en) Pyridine derivatives substituted with novel benzoxazoles or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical compositions containing the same as active ingredients for prevention and treatment of abnormal cell growth disease
BRPI0519280A2 (en) compound, pharmaceutical composition and use of a compound
Zhou et al. Fasudil hydrochloride hydrate, a Rho‐kinase inhibitor, suppresses high glucose‐induced proliferation and collagen synthesis in rat cardiac fibroblasts
BR0312000A (en) Compounds, pharmaceutical compositions, method for treating or prophylaxis of diseases, and use of the compounds
RU2014129508A (en) NEW COMBINATION
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
KR20180015461A (en) The triple layered tablet type medication for gastritis with irritable bowel syndrome and functional dyspepsia
CN106511326A (en) Repairing type disinfection liquid
CN112716956B (en) Daily-use compound preparation for treating cold and preparation method thereof
RU2011136311A (en) PHARMACEUTICAL COMPOSITIONS FOR DEHYDRATION, ATROPHY AND REMOVAL OF PATHOLOGICAL TISSUES
BR112012028652A2 (en) hydroxyalkylbenzylpyrazols and their use
WO2010044582A2 (en) Ｎ1-2-thiophene-2-ylethyl-ｎ2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredients
CN103157071B (en) Chinese herbal compound film for treating dermatomycosis and preparation method thereof
CN103599082A (en) Omeprazole and sodium bicarbonate core-covering tablet
Hajimoradi Javarsiani et al. In vitro inhibition of melanoma (B16F10) viability and colonization through combining metformin and dacarbazine
CN104147197A (en) Medicine for treating tinea pedis and preparation method thereof
WO2021212865A1 (en) Compound allicin soft capsule and method for preparing and packaging same
CN105193726B (en) A kind of pharmaceutical composition for treating onychomycosis
KR20220085094A (en) Pharmaceutical composite formulation for treating chronic rhinitis with allergic conjunctivitis